drugset

drugset / Trial / NCT00692458

A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

NCT00692458 ↗

Phase 3 Withdrawn Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to test MK0822 on reducing the risk of bone metastasis in women with breast cancer.

Timeline

Start: 2008-09
Primary completion: 2008-09
Completion: 2008-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Odanacatib	Small molecule	5 mg	Oral

Indications